DT2216 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Built to fix navitoclax's platelet problem. It hands the target protein to a cell tool that platelets barely have. In its first study, in 20 people with solid cancers, only one had a dose-limiting problem: a severe platelet drop that cleared within 48 hours.
Evidence grade for DT2216: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, 20 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 20
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 20 people given it
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Ageing and longevity, Immune system and inflammation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
DT2216 is an experimental cancer drug given by drip. It was built to kill the same cells as navitoclax without wrecking platelets, the blood cells that stop bleeding. In mice, it clears worn-out cells. It is not approved, and every study is in cancer.
What people take it for
- Cancer, which is the only use tested in people.
- A safer way to clear worn-out cells.
What studies in people showed
In the first study, 20 people with advanced cancer got it by drip twice a week. Only one had a dose-limiting problem, a severe platelet drop that cleared within 48 hours. Cancer held steady in 20 percent, and half were alive at 7.9 months. A children's cancer study was paused for side effects too harsh to accept. Nobody has tested it for ageing. In mice, it slowed tumours without a big platelet drop.
What people report
Reports, not study results
The good
- In the first study, there was no bleeding, and platelets always came back above 50,000 within four days.
The bad
- One severe platelet drop in the first study.
- A children's cancer study was paused for side effects too harsh to accept.
Where these come from: The results are from the study and registry records on this page. There are no forum reports, since the drug is only given in studies.
My bottom line
Smart drug design, and it looks gentler on platelets. But it is a cancer drug given by drip. It is not an ageing pill, and nobody has tested it as one.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals DT2216 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Living longer20 people · 1 study
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Cancer and tumours2 animal or lab studies
- Immune function1 animal or lab study
33 of the 36 indexed goals have no study of any kind behind DT2216
No study in people, animals or cells on this page reports a result for these. That does not prove DT2216 does nothing for them. It does mean anything you have heard about DT2216 and one of these did not come from a study cited here.
Show full evidence
What is DT2216?
Built to fix navitoclax's platelet problem. It hands the target protein to a cell tool that platelets barely have. In its first study, in 20 people with solid cancers, only one had a dose-limiting problem: a severe platelet drop that cleared within 48 hours.
Navitoclax kills worn-out cells and platelets, the blood cells that stop bleeding, by hitting the same protein, BCL-xL. DT2216 was designed around that. It is a two-headed molecule. One end grabs BCL-xL. The other end grabs a cell tool called VHL that tags proteins for the cell's rubbish bin. So BCL-xL gets destroyed, not just blocked. Platelets have very little VHL, so the drug should spare them.
The first study in people was published in 2025. 20 people with solid cancers that had come back or stopped responding got DT2216 through a drip twice a week, at 0.04 to 0.4 mg/kg. Their median age was 60.5, and 60 percent were women. Only one person had a dose-limiting problem: platelets dropped to dangerous levels, then recovered within 48 hours. The lowest platelet count in the first cycle ranged from 24,000 to 297,000. In every case, platelets were back above 50,000 within four days. Cancer held steady in 20 percent of patients. Half were still alive at 7.9 months. The dose picked for the next stage was 0.4 mg/kg. As of September 2026, that study is finished. An ovarian cancer study adding a second drug is recruiting. A children's cancer study has been paused, and the registry says the reason was side effects too harsh to accept.
In mice and human cells in a dish, it worked as designed. A 2019 paper found DT2216 was gentler on platelets than navitoclax in a dish, and stronger against cancer cells that need BCL-xL. It slowed several human tumours grown in mice without a big platelet drop.
No study for ageing or worn-out cells is registered for DT2216 anywhere. No clean-up drug has improved health in a proper study in people, and every DT2216 study is in cancer.
How does DT2216 work?
Shown in human cells and mice, with the platelet sparing now backed by the first study in people: DT2216 grabs BCL-xL and pulls in a cell tool called VHL. VHL tags BCL-xL so the cell destroys it. Platelets have very little VHL, so this barely happens in them. Worn-out cells that need BCL-xL die when it is gone. That is the clean-up idea, and it has been shown in mice, not in people. In the study in people, BCL-xL was destroyed in white blood cells at the top dose.
What have studies in people found about DT2216?
One published first study in 20 people with solid cancers, plus registry records for two more cancer studies. Nobody has been given DT2216 for worn-out cells or ageing, and no such study is registered.
- 20 people with solid cancers that had come back or stopped responding: one dose-limiting problem, a severe platelet drop that cleared within 48 hours. No bleeding, and no deaths from side effects. Cancer held steady in 20 percent, and half were alive at 7.9 months. Supported by the US National Institutes of Health.
- At 0.4 mg/kg, the dose picked for the next stage, BCL-xL in white blood cells was destroyed quickly and stayed down.
- DT2216 plus the chemo drug paclitaxel in ovarian cancer that no longer responds to platinum chemo: early study, recruiting as of September 2026.
- Children's Oncology Group study: paused, with the reason given as side effects too harsh to accept.
What this does not tell you: Twenty people with advanced cancer, given a drip twice a week, tell you about short-term platelet effects and side effects in that group. They do not tell you whether worn-out cells were cleared, because nobody measured that. They say nothing about what repeat doses would do to a healthy older adult. The children's study being paused for harsh side effects is a reminder that sparing platelets is not the same as being safe.
The state of the research
DT2216 is the clearest case in this field of a smart fix for a known problem being carried into people. The problem, named in 2010, was that blocking BCL-xL kills platelets. The fix, published in 2019, was to destroy BCL-xL using a tool platelets barely have. The first data in people, from 2025, fit the fix. One person had a severe platelet drop that cleared in 48 hours. On navitoclax, platelets dropped to dangerous levels in 29 of 55 patients.
That is a drug design success, not an ageing result. Every DT2216 study is in cancer. No ageing study is registered. The case for it as a clean-up drug is still all in mice. A children's cancer study is paused for harsh side effects, and that belongs on the same page as the good safety news from the first study.
The evidence, in charts
Fig. 1a · how many people
20people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Journal of Hematology and Oncology 2025 | 20 | 100% |
The whole total is one study of 20. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 3 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
4 of 6 sources here are studies in people. The rest are not.
- Study in people · done in people467%
- Animal study · done in animals233%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 5 different years, 2010 to 2026, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for DT2216, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2025First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies
DT2216 was built to spare platelets, and in its first study in people it mostly did. 20 adults with advanced solid cancers got it through a drip twice a week, at rising doses. Only one person hit a dose-limiting problem, a severe platelet drop that cleared within two days. Cancer held steady in 20 percent of patients. Half were alive at about eight months. This was a safety and dosing study, not a test of whether it helps. The US National Institutes of Health supported it.
20 patients, median age 60.5, 60 percent female, dose escalation 0.04 to 0.4 mg/kg intravenously twice weekly. One dose-limiting toxicity, a grade 4 thrombocytopenia resolving within 48 hours; lowest first-cycle platelet count 24,000 to 297,000, recovery above 50,000 within four days in all cases. Stable disease in 20 percent, median overall survival 7.9 months. Recommended phase 2 dose 0.4 mg/kg. National Institutes of Health supported.
- Study in people2026A Study of DT2216 in Relapsed/Refractory Malignancies
This is the sign-up record for the first DT2216 study in people, not a separate result. Dialectic Therapeutics ran it as an early study and enrolled 20 people. The record marks it finished and posts no results of its own. Everything known about what happened comes from the published paper.
Dialectic Therapeutics, phase 1, enrolment 20, status COMPLETED. This is the registration for the first-in-human study above. No results are posted on the registry record itself.
- Study in people2026Testing the Addition of DT2216 to Usual Chemotherapy (Children's Oncology Group)
A children's cancer study of DT2216 has been paused because of side effects. The Children's Oncology Group planned to enrol 81 young patients. The registry gives side effects too harsh to accept as the reason. We checked the record was live in September 2026. A pause for harm is a result, and it belongs next to the claim that this drug is the gentler option.
Children's Oncology Group phase 1/2, estimated enrolment 81, status SUSPENDED. The registry gives the reason as unacceptable toxicity. Verified live September 2026 and reported here because suspensions are findings.
- Study in people2010Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study
This is the study DT2216 was designed to get around. When navitoclax was given to 55 adults with lymph node cancer, platelets dropped to dangerous levels in 29 of them, and that set the dose limit. The authors traced it to the drug blocking the same protein platelets need to stay alive. DT2216 goes after that protein differently to avoid the problem. This citation is about navitoclax, not DT2216.
The comparison that explains why DT2216 exists. With navitoclax, grade 3 or 4 thrombocytopenia occurred in 29 of 55 patients and was dose-limiting, attributed by the authors to high-affinity BCL-xL inhibition in platelets.
This study gave people navitoclax, not DT2216. It is here because it belongs on the record, and it is excluded from every count on this page.
- Animal study2019A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity
In mice and in a dish. DT2216 was gentler on platelets than navitoclax in a dish, and stronger against cancer cells that need BCL-xL. It slowed human tumours grown in mice without a big platelet drop. It was designed this way because platelets have little of the cell tool it uses.
Human cell lines and mouse xenografts. DT2216 was less toxic to platelets than ABT-263 in vitro, more potent against BCL-xL-dependent cancer cells, and inhibited xenograft tumour growth in mice without appreciable thrombocytopenia. The design rationale is that VHL is poorly expressed in platelets.
- Animal study2020DT2216, a Bcl-xL-specific degrader, is highly active against Bcl-xL-dependent T cell lymphomas
In mice and in a dish. DT2216 worked against a type of lymph cancer that needs BCL-xL. That adds to the lab case for destroying the protein instead of just blocking it.
Cells and mice. Activity against BCL-xL-dependent T cell lymphoma models, extending the preclinical case for selective degradation over inhibition.
Common questions
Has DT2216 been tested in people?
Yes. 20 people given it across 1 completed trial cited here, 0 of which found nothing. Built to fix navitoclax's platelet problem. It hands the target protein to a cell tool that platelets barely have. In its first study, in 20 people with solid cancers, only one had a dose-limiting problem: a severe platelet drop that cleared within 48 hours.
What is the DT2216 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 20 people given it
Is DT2216 FDA-approved?
Not approved. Still being tested as a cancer drug. The first early safety study in people is done. It set a dose for mid-stage studies of 0.4 mg/kg, given into a vein twice a week. No study for ageing or for clearing worn-out cells is registered.
Has DT2216 been tested for ageing?
No. All three registered DT2216 studies are for cancer. No ageing or worn-out cell study is registered anywhere as of September 2026.
Did the platelet-sparing design work in people?
In the first 20 patients, it seemed to. One person had a severe platelet drop that set the dose limit, and it cleared within 48 hours. In every case, platelets were back above 50,000 within four days. For comparison, on navitoclax, platelets dropped to dangerous levels in 29 of 55 patients in its first study.
What does PROTAC mean?
It stands for a type of two-headed drug. One end grabs the target protein. The other end grabs a cell tool that tags proteins for the cell's rubbish bin. So the cell destroys the target instead of the drug just blocking it. Here the tool is VHL, picked because platelets have very little of it.
Is DT2216 safe?
Too little is known. The 20-person first study found no bleeding and no deaths from the drug. But a children's cancer study is paused, with side effects too harsh to accept given as the reason. Both facts are current as of September 2026.